Intravenous thrombolysis remains a standard treatment for acute ischemic stroke within 4.5 hours after onset. Vascular ...

Atrial fibrillation affects more than 33 million people worldwide and is a leading cause of stroke. 1 Alcohol consumption is ingrained in Western culture, with 57% of American adults drinking ...

Hereditary angioedema is a rare, potentially life-threatening disorder characterized by attacks of cutaneous and submucosal swelling. Quincke first described its clinical presentation, and Osler ...

Treatment was initiated in 308 participants per group. At week 48, HIV-1 RNA levels of 50 copies per milliliter or higher were found in 5 participants (1.6%) receiving long-acting therapy and in 3 ...

Insomnia is common and frequently occurs with other disorders. First-line cognitive behavioral therapy with or without medication can produce rapid, sustained alleviation of insomnia symptoms.

Hairy-cell leukemia, a rare B-cell cancer driven by a BRAF mutation and manifesting with cytopenias and splenomegaly, is responsive to purine analogue chemotherapy and to BRAF inhibitors combined w ...

A 74-year-old man presented for evaluation of his chronic kidney disease before a planned transcatheter aortic-valve replacement. Pancreatitis had been diagnosed 25 years earlier, and enlargement o ...

We conducted a phase 2a, multicenter, randomized, double-blind, placebo-controlled, 24-week, parallel-group trial to assess the efficacy and safety of risankizumab, an anti–interleukin-23p19 ...

The Race and Medicine collection reflects the commitmentfrom NEJM to understanding and combating racism as a public health and human rights crisis.

Retinoblastoma is a childhood retinal cancer that occurs in approximately 6 of 100,000 live births, with 250 to 300 new cases per year in the United States and approximately 8000 worldwide. 1 ...

The authors review the epidemiology, pathophysiology, and treatment of alcohol-associated hepatitis, including the evidence for glucocorticoids and liver transplantation.

The current Phase 2 Trial of Anti α-Synuclein Antibody in Early Parkinson’s Disease (PASADENA) is a three-part, randomized trial assessing the efficacy and safety of low-dose (1500 mg) and high ...